Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting ... CFO David Denton said the company is already ...

A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include ...

Pfizer reaffirming its outlook for the full year but noting it has not factored in any potential impact from tariffs. Here to discuss what these results mean for the drug maker we've got Vamul Divan.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts polled by FactSet.

Pfizer CEO Albert Bourla on Tuesday said ... the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Pfizer CEO Albert Bourla said the pharmaceutical ... the company behind fast food chains like Taco Bell and Pizza Hut, expects little impact from tariffs on its supply chain, CFO Chris Turner ...